Lunai Bioworks heads into today's earnings print wrapped in one of the most aggressive short-selling setups in the small-cap biotech universe.
Short interest has roughly doubled in the past month. It now runs at nearly 13% of free float — up from around 9% in early April — after a sharp mid-May surge that pushed the reading as high as 16.5% on May 8. The borrow market tells the same story. Cost to borrow peaked above 297% earlier this week before easing to 169% — still the kind of triple-digit rate that reflects acute scarcity of lendable shares. Availability remains well below levels that would suggest comfort for new shorts. The ORTEX short score stands at 77.7, near the top of the range it has held all month, confirming the aggregate picture is firmly bearish from a positioning standpoint.
Options traders are conspicuously absent from the fear trade. The put/call ratio is just 0.07 — barely changed from the 20-day mean of 0.076 and running close to its 52-week floor. That is the opposite of what a defensive market typically looks like ahead of a binary catalyst. It signals that options positioning is skewed almost entirely toward calls, even as the stock has shed 20% over the past month and 5% in the past week alone, closing at $0.30. The divergence between a heavily shorted lending market and a call-dominated options book is the defining tension in this setup.
History provides a sobering backdrop. The two most recent confirmed earnings reactions — February 17 and February 13, 2026 — produced single-day moves of -20% and -18%, respectively, followed by five-day drawdowns of 40% and 33%. The May 8 event showed a more modest -2.7% on the day. Ownership is concentrated, with the top three holders — Rene Sindlev, Laksya Ventures, and Serhat Gümrükcü — together controlling roughly 21% of shares outstanding, limiting the float that short sellers are ultimately competing over.
Today's print is therefore a direct test of whether the company can show any clinical or financial progress capable of interrupting a pattern of severe post-earnings selling — and whether the call-skewed options market or the aggressively positioned short base has read the catalyst correctly.
See the live data behind this article on ORTEX.
Open LNAI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
